

Collusia Leadership

Lisa Solein

Chief Executive Officer



Lisa Solein serves as Collusia's Chief Executive Officer. She has been responsible for the company's targeted expansion into bioengineering and sustainability research.

Prior to joining Collusia, Ms. Solein acted as advisory counsel for the U.S. Food and Drug Administration (FDA). She is currently the chairperson of the Global Trust for a Better Planet. She also serves on the board of trustees of Northeast Family Help and

Hope, a non-profit organization providing assistance to homeless families.

Angelie Bonneville, Ph.D.

Executive Vice President, Discovery Research



Angelie Bonneville, Ph.D., has served as Collusia's Vice President of Research and Development for five years. She currently serves as Senior Vice President of Collusia's Discovery Research division.

Dr. Bonneville oversees the TimeTilter™ initiative. She also co-founded and now serves on the Board of Trustees of the multinational Timeline of the Future Institute.

Peter Casein

Executive Vice President, Marketing and Communications



Peter Casein serves as Collusia's Senior Vice President of Marketing and Communications. Mr. Casein oversees Collusia's Programming the Future initiative and directs the TimeTilter™ launch campaign. He serves as an Advisory Board Member of WEcan: Engaging Women Engineers.

Piper Swervionous, M.D.

Executive Vice President, Clinical Research



Piper Swervionous, M.D., joined Collusia in 2016 as Executive Vice President of Clinical Research. Dr. Swervionous specializes in metabolic and ophthalmic enhancement. She is the 2015 recipient of the U.S. Surgeon Association's National Cutting Edge Pioneers Award.

Ed Worthenfold

Executive Vice President, Strategy and Regulatory Division



Ed Worthenfold serves as the Executive Vice President for Collusia's Strategy and Regulatory Division. Mr. Worthenfold oversees public policy and regulatory approval for Collusia's investigational products and research. He has served in Washington, D.C. as legal counsel on federal regulatory issues.